Merck Q2 ’20 Earnings Update
Merck hosted its Q2 ’20 earnings call (press release; slides) but did not provide any update to its diabetes business beyond the financial performance of its Januvia and Steglatro franchises. Unsurprisingly, much of the call was focused on the company’s COVID-19 vaccine development and oncology portfolio. Below, FENIX provides diabetes-related financial highlights and insights from the call.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.